Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
Jarushka Naidoo, Scott Antonia, Yi‐Long Wu, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 5, pp. 657-663
Open Access | Times Cited: 62

Showing 26-50 of 62 citing articles:

Advances and future directions in ROS1 fusion-positive lung cancer
M. Boulanger, Jaime L. Schneider, W. Marston Linehan
The Oncologist (2024) Vol. 29, Iss. 11, pp. 943-956
Open Access | Times Cited: 3
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, et al.
Current Oncology (2024) Vol. 31, Iss. 9, pp. 5121-5139
Open Access | Times Cited: 3
Stage III NSCLC treatment options: too many choices
Oke Dimas Asmara, Georgia Hardavella, Sara Ramella, et al.
Breathe (2024) Vol. 20, Iss. 3, pp. 240047-240047
Open Access | Times Cited: 3
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
Terufumi Kato, Ignacio Casarini, Manuel Cobo, et al.
Lung Cancer (2023) Vol. 187, pp. 107414-107414
Open Access | Times Cited: 7
The role of chemoradiotherapy and immunotherapy in stage III NSCLC
Zsuzsanna Orosz, Árṕad Kov́acs
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 2
A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation‐positive non‐small cell lung cancer (stage III) who have not progressed following definitive, platinum‐based, chemoradiation therapy (PLATINUM trial)
Juwhan Choi, Jeong Eun Lee, Chang‐Min Choi, et al.
Thoracic Cancer (2022) Vol. 13, Iss. 23, pp. 3431-3435
Open Access | Times Cited: 9
A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer
Valentina Bartolomeo, Francesco Cortiula, Lizza E.L. Hendriks, et al.
International Journal of Radiation Oncology*Biology*Physics (2023) Vol. 118, Iss. 5, pp. 1455-1460
Closed Access | Times Cited: 4
Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists
Udit Nindra, Victoria Bray, Deme Karikios, et al.
Oncology (2024) Vol. 102, Iss. 8, pp. 732-736
Closed Access | Times Cited: 1
Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
Yao Li, Yaping Long, Xiangwei Ge, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1412-1412
Open Access | Times Cited: 1
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
Danielle Brazel, Sai‐Hong Ignatius Ou
Lung Cancer Targets and Therapy (2023) Vol. Volume 14, pp. 63-69
Open Access | Times Cited: 3
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles
Andreas M Heilmann, Jonathan W. Riess, Margaret E. McLaughlin-Drubin, et al.
The Oncologist (2023) Vol. 29, Iss. 2, pp. e224-e236
Open Access | Times Cited: 3
EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB–IIIA non-small cell lung cancer in Norway–a nationwide cohort study
Åslaug Helland, Tor Åge Myklebust, Simona Conte, et al.
Cancer Treatment and Research Communications (2023) Vol. 38, pp. 100785-100785
Open Access | Times Cited: 3
Surgery patterns and survival of T4N2 non-small cell lung cancer – A population-based analysis
Chenxi Zhang, Meiqing Zhang, Jingxuan Chen, et al.
Clinical Surgical Oncology (2024) Vol. 3, Iss. 1, pp. 100034-100034
Open Access
Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017
Ronald Damhuis, Chris Dickhoff, Idris Bahce, et al.
Lung Cancer (2024) Vol. 190, pp. 107532-107532
Closed Access
The expanding importance of tissue sample analysis for biomarker testing in non-small cell lung cancer management and survival
Augusto Valdivia, Ilaria Priano, Núria Pardo, et al.
Barcelona Respiratory Network (2024) Vol. 10, Iss. 1
Open Access
Significance of Immune Checkpoints in Lung Cancer
Anastasios Dimou, Konstantinos Leventakos
Springer eBooks (2024), pp. 109-123
Closed Access
Treatment of cavitated non-small cell lung cancer presenting as “Halloween pumpkin” following the consecutive NEOADAURA and ADAURA2 strategy: A case report
Lingyun Wei, Nan Yang, Chuan Gao, et al.
Respiratory Medicine Case Reports (2024) Vol. 51, pp. 102089-102089
Open Access
Systemic treatment of EGFR-mutated non-small cell lung cancer
Rafał Czyżykowski, Ewa Wrona, A Tałajko, et al.
Oncology in Clinical Practice (2024)
Open Access
Osimertinib significantly improves PFS in patients with unresectable stage III EGFR-mutated NSCLC
Marten Dooper
(2024)
Closed Access
Stellenwert einer „targeted therapy“ beim EGFR-mutierten Lungenkarzinom nach erfolgter Radiochemotherapie
Jörg Andreas Müller, Dirk Vordermark
Strahlentherapie und Onkologie (2024) Vol. 200, Iss. 10, pp. 921-923
Open Access
Osimertinib in Stage III EGFR -Mutated NSCLC — Game, Set, Match
Natasha B. Leighl
New England Journal of Medicine (2024) Vol. 391, Iss. 7, pp. 652-654
Closed Access
PROshot: Immunotherapy for Cervical Cancer, Epidermal Growth Factor Receptor-Mutated Stage III Lung Cancer, Perioperative Chemotherapy for Esophageal Cancer, Salvage Postprostatectomy Radiation and Androgen Deprivation Therapy, and Immunotherapy for Head and Neck Cancer
Laura Dover, Caleb Dulaney
Practical Radiation Oncology (2024) Vol. 14, Iss. 5, pp. 363-367
Closed Access
Recapping Radiation Related Abstracts at ASCO 2024: A Commentary about the Fundamental Role of Radiation Therapy in Esophageal and Lung Cancers
Salma K. Jabbour, Kristin A. Higgins, Sue S. Yom, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 120, Iss. 2, pp. 309-314
Closed Access
Place de l’immunothérapie dans les CBNPC de stade III non résécables
M. Pérol, Jonathan Khalifa, H. Léna
Revue des Maladies Respiratoires Actualités (2024) Vol. 16, Iss. 2, pp. 2S161-2S168
Closed Access
Exciting progress in targeted therapy innovation for unresectable stage III EGFR‐mutated NSCLC: the phase III LAURA study
Ziyan Tong, Ning Zhu, Hong Shen, et al.
Cancer Communications (2024)
Open Access

Scroll to top